Skip to main content
SpringerLink
Log in

Also the very elderly benefit from warfarin in atrial fibrillation

  • Editorial
  • Published:
Netherlands Heart Journal Aims and scope Submit manuscript

Abstract

Warfarin therapy is the cornerstone in the prevention of thromboembolism in patients with atrial fibrillation. It reduces the risk of stroke by two thirds in comparison with no anticoagulation. 1 A weak alternative to warfarin is aspirin, which is also effective over placebo in the prevention of stroke in atrial fibrillation. 1 Aspirin is safer than warfarin in general use. The incidence of atrial fibrillation sharply increases with age, but also the risk of bleeding from warfarin shows the same pattern.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Lip GY, Hart RG, Conway DS. Antithrombotic therapy for atrial fibrillation. BMJ 2002 325:1022-5.

    Google Scholar 

  2. De Caterina R, Husted S, Wallentin, L, et al. Anticoagulants in heart disease: current status and perspectives. Eur Heart J 2007;28:880-913.

    Google Scholar 

  3. Hellemons BSP, Langenberg M, Lodder J, et al. Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin. BMJ 1999;319:175-8.

    Google Scholar 

  4. Garcia D, Hylek E. Stroke prevention in elderly patients with atrial fibrillation. Lancet 2007;370:460-1.

    Google Scholar 

  5. Mant J, Hobbs R, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007; 370:493-503.

    Google Scholar 

  6. Wysowski DK, Nourjah P, Swartz L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Intern Med 2007;167:1414-9.

    Google Scholar 

  7. SPORTIF-III Investigators. Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation (SPORTIF-III): randomised controlled trial. Lancet 2003;362: 1691-8.

    Google Scholar 

  8. Albers GW, Diener HC, Frison L, et al. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 2005;293:690-8.

    Google Scholar 

  9. Agnelli G, Gallus A, Goldhaber SZ, et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study. Circulation 2007;116:180-7.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. www.bsl.nl/shop/

    F. W. A. Verheugt

Authors
  1. F. W. A. Verheugt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to F. W. A. Verheugt.

Additional information

Department of Cardiology, Heart Lung Centre, Radboud University Medical Centre, Nijmegen, the Netherlands

Correspondence to: F.W.A. Verheugt 670 Cardiology, Heart Lung Centre, Radboud University Medical Centre, PO Box 9101, 500 HB Nijmegen, the Netherlands

Rights and permissions

Reprints and permissions

About this article

Cite this article

Verheugt, F.W.A. Also the very elderly benefit from warfarin in atrial fibrillation. NHJL 15, 403–404 (2007). https://doi.org/10.1007/BF03086039

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03086039

Search

Navigation